- MAHA served as the exclusive sell-side advisor to Innovo Detox in its sale to R&S Holdings Inc. dba Project Chesapeake.
- Innovo Detox is a Pennsylvania-based provider of substance use disorder treatment and drug and alcohol rehabilitation services.
- The acquisition adds an established clinical operation to Chesapeake’s growing behavioral health platform.
LOS ANGELES, October 13, 2026 / PRNewswire / M&A Healthcare Advisors (MAHA), a FINRA-licensed investment bank focused on the healthcare industry, is pleased to announce the sale of Innovo Detox (Innovo), a Pennsylvania-based provider of substance use disorder (SUD) treatment and drug and alcohol rehabilitation services, to R&S Holdings Inc. dba Project Chesapeake (Chesapeake), a behavioral health organization dedicated to expanding access to high-quality addiction treatment services across the Mid-Atlantic region.
MAHA served as the exclusive sell-side advisor to Innovo, with the engagement led by Andre Ulloa, Managing Director, and Mike Abud, Senior Associate.
Innovo has built a strong reputation for clinical quality and patient care in the Pennsylvania SUD treatment market. Those qualities made the company an attractive acquisition opportunity for buyers seeking to grow in the behavioral health space, and Chesapeake emerged as the right strategic partner to support Innovo’s next phase of growth.
“We identified Chesapeake early in the process as a strong strategic fit for Innovo given its commitment to the substance use disorder sector and its vision for growing a quality behavioral health platform,” said Andre Ulloa. “There was strong alignment between the two organizations from the outset. We are proud to have represented Innovo and to have helped bring together two organizations committed to expanding access to high-quality addiction treatment.”
The transaction required careful structuring to deliver a clean, standalone acquisition. MAHA coordinated a comprehensive diligence process and worked closely with legal counsel on both sides to maintain deal momentum, address issues as they arose, and bring the transaction to a successful close on an accelerated timeline.
“M&A Healthcare Advisors ran our process with precision and a real command of every detail,” said Eric Spofford, Founder of Innovo Detox. “They understood the clinical and regulatory realities of the business, kept a complicated transaction moving on a quick timeline, and consistently protected our position at the table. When it came time to close, they delivered. I would work with them again.”
For Chesapeake, the acquisition adds an established clinical operation to its growing behavioral health platform.
“MAHA brought us an opportunity that checked every box on our acquisition criteria,” said Joe Rogers, Principal of R&S Holdings Inc. “Their team was organized, professional, and kept the process on track from start to finish. We look forward to building on the strong foundation Innovo has established.”
Navigating behavioral health M&A presents unique challenges, from licensing and regulatory considerations to the revenue cycle complexities of commercial insurance reimbursement. Addiction treatment acquisitions in particular require an advisor who understands both the transaction mechanics and the clinical operations behind them. Throughout the process, MAHA worked daily to facilitate communication between the parties and to foster a productive working relationship between buyer and seller.
About Innovo Detox
Polaris Detox LLC, doing business as Innovo Detox, is a Pennsylvania-based provider of substance use disorder and drug and alcohol rehabilitation services. Innovo provides residential and clinical treatment services to patients across the region, with a strong reputation for patient care and clinical outcomes.
About R&S Holdings Inc. dba Project Chesapeake
R&S Holdings Inc. dba Project Chesapeake is a behavioral healthcare organization committed to expanding access to high-quality substance use disorder treatment services. With an established presence in the Mid-Atlantic region, Chesapeake pursues strategic acquisitions of well-run clinical operations that share its mission of delivering meaningful, lasting care to patients and communities in need.
About M&A Healthcare Advisors
M&A Healthcare Advisors (MAHA) is a FINRA-licensed investment bank focused exclusively on the healthcare industry. MAHA specializes in Sell-Side Representation, M&A Consultation, Valuation, and other Investment Banking Services in the lower middle market healthcare industry. Headquartered in Los Angeles, California, MAHA serves healthcare operators and investors nationwide.
The founders at M&A Healthcare Advisors have sold companies in a variety of healthcare verticals including Behavioral Health, Substance Use Disorder Treatment, Autism Services, I/DD, Hospice, Home Health, Home Care, Private Duty, Physician Practices, Plastic Surgery, Med Spa, Staffing, and all types of Pharmacy.
